ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
Alnylam Pharmaceuticals, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
और पढ़ें
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
History
The company is a spin-off from the Max Planck Institute for Biophysical Chemistry. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders, and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy. In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
On October 10, 2018, Alnylam appoints Margaret Hamburg to Board of Directors. Prior to this, from May 2009 to April 2015, she serves as Commissioner of the U.S. Food and Drug Administration (FDA).
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.
In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.
In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.
Products
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.
Patisiran
In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).
In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
FDA on patisiran for cardiomyopathy
In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA. The committee meeting chose to deny approval for the treatment of cardiomyopathy of ATTR amyloidosis with patisiran. Note that while patisiran was denied for the indication of cardiomyopathy, it remains an FDA approved treatment for polyneuropathy.
Vutrisiran
Alnylam went on to pursue the development of vutrisiran, which received FDA approval in 2022 and accounted for the majority of reported profit compared to patisiran/Onpattro in 2025.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
ALNY स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
ALNY स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
ALNY विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 8 21.6%
- खरीदें 21 56.8%
- होल्ड 8 21.6%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
24 विश्लेषक · 2026-08-14Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $1.21 | $1.59 | -0.38% |
| 31 मार्च 2026 | $1.51 | $0.98 | 0.53% |
| 31 दिसमबर 2025 | $0.82 | $1.15 | -0.33% |
| 30 सितमबर 2025 | $2.11 | $0.76 | 1.3% |
| 30 जून 2025 | $-0.51 | $-0.73 | 0.22% |
| 31 मार्च 2025 | $-0.44 | $-1.03 | 0.59% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
बैलेंस शीट 23
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
नकदी प्रवाह 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
तरलता और शोधन क्षमता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
दक्षता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
विकास दरें 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
आय विवरण 17
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
बैलेंस शीट 22
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
नकदी प्रवाह 12
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
तरलता और शोधन क्षमता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
दक्षता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| परिचालन मार्जिन % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| शुद्ध आय | $314M | $-278M | $-440M | $-1.13B | $-853M |
| तनुकरणित EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| त्वरित अनुपात | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $465M | $-43M | $42M | $-613M | $-718M |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 877 फाइलर्स · $27.2B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 99 (-17 पिछली तिमाही की तुलना में) | 77 (-68 पिछली तिमाही की तुलना में) | 330 (+5 पिछली तिमाही की तुलना में) | 261 (+5 पिछली तिमाही की तुलना में) | +2.3M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| Capital World Investors | $3354715611 | 11144846 | 12.36% | शेयर |
| FMR LLC | $3108157652 | 10325076 | 11.45% | शेयर |
| Capital Research Global Investors | $2935115324 | 9750699 | 10.81% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1968251542 | 6538390 | 7.25% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $1815053762 | 6029478 | 6.69% | शेयर |
| STATE STREET CORP | $1070369060 | 3555689 | 3.94% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $686853582 | 2288725 | 2.53% | शेयर |
| NORGES BANK | $683883867 | 2271813 | 2.52% | शेयर |
| WELLINGTON MANAGEMENT GROUP LLP | $614923915 | 2042733 | 2.26% | शेयर |
| Dodge & Cox | $588631955 | 1955393 | 2.17% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $564713315 | 1875937 | 2.08% | शेयर |
| AMERICAN CENTURY COMPANIES INC | $558098292 | 1853956 | 2.06% | शेयर |
| TWO SIGMA ADVISERS, LP | $450362484 | 1132560 | 1.66% | शेयर |
| Clearbridge Investments, LLC | $379142285 | 1259483 | 1.40% | शेयर |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269059154 | 893795 | 0.99% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $259723265 | 862782 | 0.96% | शेयर |
| Deep Track Capital, LP | $248349750 | 825000 | 0.91% | शेयर |
| Qube Research & Technologies Ltd | $240437176 | 798715 | 0.89% | शेयर |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219642021 | 729635 | 0.81% | शेयर |
| BANK OF AMERICA CORP /DE/ | $176408397 | 586016 | 0.65% | शेयर |
| LOOMIS SAYLES & CO L P | $170456431 | 566244 | 0.63% | शेयर |
| BAILLIE GIFFORD & CO | $165849468 | 550940 | 0.61% | शेयर |
| ROYAL BANK OF CANADA | $154998000 | 514893 | 0.57% | शेयर |
| Polar Capital Holdings Plc | $145322534 | 482751 | 0.54% | शेयर |
| Paradigm Biocapital Advisors LP | $144494400 | 480000 | 0.53% | शेयर |
| D. E. Shaw & Co., Inc. | $129533209 | 430300 | 0.48% | कॉल ऑप्शन |
| FIRST TRUST ADVISORS LP | $126894361 | 421534 | 0.47% | शेयर |
| Swiss National Bank | $112609302 | 374080 | 0.41% | शेयर |
| WELLS FARGO & COMPANY/MN | $111381100 | 370000 | 0.41% | कॉल ऑप्शन |
| BlackRock, Inc. | $102807465 | 341519 | 0.38% | शेयर |
| CANADA PENSION PLAN INVESTMENT BOARD | $100618073 | 334246 | 0.37% | शेयर |
| Sumitomo Mitsui Trust Group, Inc. | $97948840 | 325379 | 0.36% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97804647 | 324900 | 0.36% | कॉल ऑप्शन |
| Legal & General Group Plc | $97467493 | 323780 | 0.36% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $95125781 | 316001 | 0.35% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $94687695 | 314546 | 0.35% | शेयर |
| Candriam S.C.A. | $94586456 | 314512 | 0.35% | शेयर |
| D. E. Shaw & Co., Inc. | $93229593 | 309702 | 0.34% | शेयर |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90367000 | 300193 | 0.33% | शेयर |
| DEUTSCHE BANK AG\ | $89849026 | 298472 | 0.33% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88641294 | 294460 | 0.33% | शेयर |
| Pictet Asset Management Holding SA | $83257214 | 278613 | 0.31% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $81586054 | 271023 | 0.30% | शेयर |
| GILDER GAGNON HOWE & CO LLC | $80992374 | 269051 | 0.30% | शेयर |
| CONGRESS ASSET MANAGEMENT CO | $79983972 | 265701 | 0.29% | शेयर |
| VANGUARD ASSET MANAGEMENT, Ltd | $77578441 | 257710 | 0.29% | शेयर |
| California Public Employees Retirement System | $76477575 | 254053 | 0.28% | शेयर |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75974872 | 252383 | 0.28% | शेयर |
| Korea Investment CORP | $74553090 | 247660 | 0.27% | शेयर |
| Woodline Partners LP | $74138270 | 246282 | 0.27% | शेयर |
| Squarepoint Ops LLC | $70440719 | 233999 | 0.26% | शेयर |
| TD Asset Management Inc | $70349507 | 233696 | 0.26% | शेयर |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65136061 | 196863 | 0.24% | शेयर |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64296696 | 213589 | 0.24% | शेयर |
| National Pension Service | $59692744 | 198295 | 0.22% | शेयर |
| PINEBRIDGE INVESTMENTS LLC | $58914280 | 195709 | 0.22% | शेयर |
| Robeco Institutional Asset Management B.V. | $56618929 | 188084 | 0.21% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53824164 | 178800 | 0.20% | पुट ऑप्शन |
| VICTORY CAPITAL MANAGEMENT INC | $52030628 | 172842 | 0.19% | शेयर |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50772924 | 168664 | 0.19% | शेयर |
| RHUMBLINE ADVISERS | $49844185 | 165579 | 0.18% | शेयर |
| Life Cycle Investment Partners Ltd | $49797587 | 165424 | 0.18% | शेयर |
| ANTIPODES PARTNERS Ltd | $49228339 | 163533 | 0.18% | शेयर |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47228883 | 157223 | 0.17% | शेयर |
| CAPITAL FUND MANAGEMENT S.A. | $46931781 | 155904 | 0.17% | शेयर |
| Assenagon Asset Management S.A. | $46868866 | 155695 | 0.17% | शेयर |
| Vinva Investment Management Ltd | $45487381 | 154972 | 0.17% | शेयर |
| JANUS HENDERSON GROUP PLC | $43671202 | 132000 | 0.16% | शेयर |
| Hudson Bay Capital Management LP | $42204406 | 140200 | 0.16% | शेयर |
| ENVESTNET ASSET MANAGEMENT INC | $41059106 | 136395 | 0.15% | शेयर |
| ProShare Advisors LLC | $38686569 | 128514 | 0.14% | शेयर |
| GOLDMAN SACHS GROUP INC | $37029700 | 123010 | 0.14% | शेयर |
| LMR Partners LLP | $35881572 | 119196 | 0.13% | शेयर |
| Man Group plc | $35798187 | 118919 | 0.13% | शेयर |
| HSBC HOLDINGS PLC | $35754282 | 120600 | 0.13% | पुट ऑप्शन |
| SCS Capital Management LLC | $34783715 | 115549 | 0.13% | शेयर |
| AVIVA PLC | $34477568 | 114532 | 0.13% | शेयर |
| Davern Capital Partners, LP | $34041978 | 113085 | 0.13% | शेयर |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33770750 | 112184 | 0.12% | शेयर |
| Longaeva Partners L.P. | $33191869 | 110261 | 0.12% | शेयर |
| 683 Capital Management, LLC | $32360725 | 107500 | 0.12% | पुट ऑप्शन |
| MARSHALL WACE, LLP | $32215929 | 107019 | 0.12% | शेयर |
| HighTower Advisors, LLC | $31621666 | 105045 | 0.12% | शेयर |
| Bridgewater Associates, LP | $29977772 | 99584 | 0.11% | शेयर |
| Prosight Management, LP | $29525022 | 98080 | 0.11% | शेयर |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28956123 | 96408 | 0.11% | शेयर |
| Andra AP-fonden | $28685436 | 86697 | 0.11% | शेयर |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28376894 | 94266 | 0.10% | शेयर |
| AMERIPRISE FINANCIAL INC | $28191159 | 93649 | 0.10% | शेयर |
| BARCLAYS PLC | $27979234 | 92945 | 0.10% | शेयर |
| TREMBLANT CAPITAL GROUP | $27977728 | 92940 | 0.10% | शेयर |
| FIL Ltd | $27652616 | 91860 | 0.10% | शेयर |
| Balyasny Asset Management L.P. | $26945195 | 89510 | 0.10% | शेयर |
| Caisse de depot et placement du Quebec | $25812720 | 85748 | 0.10% | शेयर |
| Mitsubishi UFJ Trust & Banking Corp | $24911136 | 82753 | 0.09% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $24661883 | 81925 | 0.09% | शेयर |
| CITADEL ADVISORS LLC | $24564048 | 81600 | 0.09% | कॉल ऑप्शन |
| VANGUARD GROUP INC | $24356460 | 61251 | 0.09% | शेयर |
| NEOS Investment Management LLC | $23562822 | 78274 | 0.09% | शेयर |
| JONES FINANCIAL COMPANIES LLLP | $23444213 | 80462 | 0.09% | शेयर |
कंपनी के अंदरूनी सूत्र 41 इनसाइडर्स · 1 अधिकारी · 13 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | 6 अप्रैल 2026 S | 9443 | 0 | 14 | $-1274343 |
| Colleen F Reitan | निदेशक | 20 मई 2026 A | 1446 | 0 | 0 | $0 |
| Charles Elliott Sigal | निदेशक | 20 मई 2026 A | 1446 | 0 | 0 | $0 |
| Stuart A Arbuckle | निदेशक | 20 मई 2026 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | निदेशक | 20 मई 2026 A | 1446 | 0 | 0 | $0 |
| Amy Schulman | निदेशक | 20 मई 2026 A | 24049 | 0 | 0 | $0 |
| Dennis A Ausiello | निदेशक | 20 मई 2026 A | 1582 | 0 | 0 | $0 |
| Margaret A Hamburg | निदेशक | 20 मई 2026 A | 1582 | 0 | 0 | $0 |
| KELLOGG PETER N | निदेशक | 20 मई 2026 A | 1446 | 0 | 0 | $0 |
| David E I Pyott | निदेशक | 20 मई 2026 A | 1582 | 0 | 0 | $0 |
| Victor J Dzau | निदेशक | 21 जून 2012 A | — | 0 | 0 | $0 |
| Peter Barrett | निदेशक | 1 जून 2006 A | 5293 | 0 | 0 | $0 |
| John E Berriman | निदेशक | 8 जून 2005 A | 2475 | 0 | 0 | $0 |
| Christoph H Westphal | निदेशक | 3 जून 2004 C | 2409970 | 0 | 0 | $0 |
| Sanofi | 10% मालिक | 31 मई 2017 P | 10554134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | 10% मालिक | 23 फ़रवरी 2016 S | 4896716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | 10% मालिक | 3 जून 2004 C | 2409970 | 0 | 0 | $0 |
| CHP II LP | 10% मालिक | 27 मई 2004 P | 232500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | 10 अगस्त 2018 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | 10 अगस्त 2018 A | 9030 | 0 | 0 | $0 |
| John Maraganore | — | 10 अगस्त 2018 A | 151297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | 9 मार्च 2018 M | 140795 | 0 | 0 | $0 |
| Michael Mason | — | 4 जनवरी 2018 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | 29 दिसमबर 2017 M | 14500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | 20 दिसमबर 2017 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | 20 दिसमबर 2016 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 19 नवमबर 2015 G | 306996 | 0 | 0 | $0 |
| Marsha Fanucci | — | 1 जून 2015 A | 10000 | 0 | 0 | $0 |
| Steven M Paul | — | 1 जून 2015 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | 1 जून 2015 A | — | 0 | 0 | $0 |
| John K Clarke | — | 1 जून 2015 A | 2091868 | 0 | 0 | $0 |
| Kevin P Starr | — | 1 जून 2015 A | — | 0 | 0 | $0 |
| Laurence Reid | — | 19 मई 2014 M | 3905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | 8 दिसमबर 2010 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | 8 दिसमबर 2010 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | 18 जून 2010 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | 2 जून 2010 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | 11 जून 2009 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | 9 दिसमबर 2008 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | 7 दिसमबर 2005 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | 3 जून 2004 C | 18745 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 2 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 फाइलिंग | 14 फ़रवरी 2007 | — | प्रारंभिक फाइलिंग | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | 15 फ़रवरी 2006 | — | प्रारंभिक फाइलिंग | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 150 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| NUMG · Nushares ETF Trust | 3.23% | 36910 NS | 30 अप्रैल 2026 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3.19% | 10523 NS | 31 मई 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2.79% | 3791 NS | 31 मई 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2.01% | 3468 NS | 30 अप्रैल 2026 | N-PORT |
| BIB · ProShares Trust | 2.01% | 4904 NS | 31 मई 2026 | N-PORT |
| FDG · AMERICAN CENTURY ETF TRUST | 1.94% | 26515 NS | 31 मई 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1.40% | 824 NS | 30 अप्रैल 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1.29% | 15623 NS | 30 अप्रैल 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1.24% | 2379 NS | 30 अप्रैल 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1.14% | 1954 NS | 31 मई 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 1.08% | 966 NS | 30 अप्रैल 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.90% | 15151 NS | 30 अप्रैल 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0.89% | 35072 NS | 30 अप्रैल 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0.80% | 6062 NS | 30 अप्रैल 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0.76% | 613330 NS | 31 मई 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.66% | 60901 NS | 30 अप्रैल 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0.58% | 11032 NS | 30 अप्रैल 2026 | N-PORT |
| UPSD · ETF Series Solutions | 0.44% | 1435 NS | 30 अप्रैल 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0.43% | 4118 NS | 31 मई 2026 | N-PORT |
| QFLR · Innovator ETFs Trust | 0.39% | 6430 NS | 30 अप्रैल 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.38% | 10723 NS | 30 अप्रैल 2026 | N-PORT |
| SMIZ · Zacks Trust | 0.31% | 2688 NS | 31 मई 2026 | N-PORT |
| ESLG · Strategy Shares | 0.31% | 196 NS | 30 अप्रैल 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.31% | 112 NS | 30 अप्रैल 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.30% | 305 NS | 30 अप्रैल 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.28% | 94 NS | 31 मई 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0.26% | 404 NS | 30 अप्रैल 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0.24% | 2252 NS | 30 अप्रैल 2026 | N-PORT |
| ESUM · Strategy Shares | 0.23% | 1141 NS | 30 अप्रैल 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0.23% | 45231 NS | 30 अप्रैल 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.22% | 15559 NS | 30 अप्रैल 2026 | N-PORT |
| QCLR · Global X Funds | 0.21% | 27 NS | 30 अप्रैल 2026 | N-PORT |
| QYLG · Global X Funds | 0.21% | 953 NS | 30 अप्रैल 2026 | N-PORT |
| QRMI · Global X Funds | 0.21% | 108 NS | 30 अप्रैल 2026 | N-PORT |
| QYLD · Global X Funds | 0.20% | 54832 NS | 30 अप्रैल 2026 | N-PORT |
| QTR · Global X Funds | 0.20% | 19 NS | 30 अप्रैल 2026 | N-PORT |
| PTNQ · Pacer Funds Trust | 0.20% | 8062 NS | 30 अप्रैल 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0.20% | 11478 NS | 31 मई 2026 | N-PORT |
| CRTC · DBX ETF Trust | 0.19% | 810 NS | 31 मई 2026 | N-PORT |
| QSIX · Pacer Funds Trust | 0.18% | 106 NS | 30 अप्रैल 2026 | N-PORT |
| ESLV · Strategy Shares | 0.17% | 65 NS | 30 अप्रैल 2026 | N-PORT |
| GSLC · Goldman Sachs ETF Trust | 0.17% | 88082 NS | 31 मई 2026 | N-PORT |
| IQQQ · ProShares Trust | 0.15% | 2129 NS | 31 मई 2026 | N-PORT |
| SFY · Tidal Trust I | 0.15% | 3283 NS | 31 मई 2026 | N-PORT |
| GGUS · Goldman Sachs ETF Trust | 0.15% | 2232 NS | 31 मई 2026 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.14% | 5940 NS | 30 अप्रैल 2026 | N-PORT |
| TMFC · RBB Fund, Inc. | 0.14% | 9918 NS | 31 मई 2026 | N-PORT |
| FLCG · Federated Hermes ETF Trust | 0.14% | 2655 NS | 31 मई 2026 | N-PORT |
| SCHG · SCHWAB STRATEGIC TRUST | 0.14% | 282385 NS | 31 मई 2026 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0.13% | 1310 NS | 30 अप्रैल 2026 | N-PORT |